Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Idorsia Ltd    IDIA   CH0363463438

IDORSIA LTD (IDIA)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
07/09/2018 07/10/2018 07/11/2018 07/12/2018 07/13/2018 Date
26.66(c) 26.96(c) 25.38(c) 25.68(c) 26.38(c) Last
105 497 247 814 1 504 463 563 286 491 953 Volume
+0.60% +1.13% -5.86% +1.18% +2.73% Change
More quotes
Financials (CHF)
Sales 2018 27,3 M
EBIT 2018 -382 M
Net income 2018 -397 M
Finance 2018 355 M
Yield 2018 -
Sales 2019 34,7 M
EBIT 2019 -408 M
Net income 2019 -407 M
Finance 2019 143 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 98,4x
EV / Sales2019 83,5x
Capitalization 3 043 M
More Financials
Company
Idorsia Ltd. is a biopharmaceutical company engages in the development of medicines.The company engages in the discovery and development of small molecules used for therapeutic products.It focuses on diseases such as hypertension, systemic lupus erythematosus, chronic insomnia, Aneurysmal... 
More about the company
Surperformance© ratings of Idorsia Ltd
Trading Rating : Investor Rating :
More Ratings
Latest news on IDORSIA LTD
07/12IDORSIA : successfully completes the offering of new shares and the offering of ..
AQ
07/11VEEVA : Idorsia Implements Veeva Development Cloud in Less Than 12 Months
AQ
07/11IDORSIA : successfully completes the offering of new shares and the offering of ..
GL
07/11IDORSIA : successfully completes the offering of new shares and the offering of ..
AQ
07/10IDORSIA : launches the offering of new shares in combination with the offering o..
GL
06/21IDORSIA : initiates PRECISION - Phase 3 study with aprocitentan for resistant hy..
AQ
06/20IDORSIA : initiates PRECISION - Phase 3 study with aprocitentan for resistant hy..
GL
06/18IDORSIA : is initiating REACT - Phase 3 registration study with clazosentan
GL
06/18IDORSIA : is initiating REACT - Phase 3 registration study with clazosentan
AQ
06/15IDORSIA : Starts Phase 3 Registration Program with Nemorexant for Insomnia
AQ
More news
Sector news : Bio Therapeutic Drugs
07/09LONZA : restates 2017 figures after changing accounting standard
RE
07/03Sanofi beefs up diabetes pipeline to retrieve success
RE
06/29European stocks shrug off trade worries with quarterly gain
RE
06/29GILEAD SCIENCES : Rival Novartis, Gilead CAR-T therapies win European panel reco..
RE
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
07/11[email protected] goes big, seeks $525M in stock, bond offering to fund its slew of p.. 
07/11UPDATE 1-Idorsia CEO accelerates fundraising with 505 mln Sfr deal  
07/11Idorsia raises 505 mln Sfr from shares, bonds to fund pipeline  
06/19RPT-FOCUS-After split from Actelion, Idorsia CEO plans to raise more cash in .. 
06/19After split from Actelion, Idorsia CEO plans to raise more cash in 2019
1
More tweets
Qtime:52
News from SeekingAlpha
06/19Idorsia (IDRSF) clazosentan Phase 3 trial update - Slideshow 
02/07Idorsia AG 2017 Q4 - Results - Earnings Call Slides 
Chart IDORSIA LTD
Duration : Period :
Idorsia Ltd Technical Analysis Chart | IDIA | CH0363463438 | 4-Traders
Technical analysis trends IDORSIA LTD
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 22,6  CHF
Spread / Average Target -12%
EPS Revisions
Managers
NameTitle
Jean-Paul Clozel Chief Executive Officer & Director
Jean-Pierre Garnier Chairman
André C. Muller Chief Financial Officer & Executive Vice President
Martine Clozel Chief Scientific Officer & Executive VP
Robert J. Bertolini Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
IDORSIA LTD3.65%3 036
GILEAD SCIENCES8.01%100 614
VERTEX PHARMACEUTICALS20.45%45 997
REGENERON PHARMACEUTICALS-2.53%38 951
GENMAB5.49%10 457
NEUROCRINE BIOSCIENCES, INC.32.48%9 250